NCT05866354View on ClinicalTrials.gov

To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 16, 2023

Primary Completion Date

November 2, 2023

Study Completion Date

November 2, 2023

Conditions

Solid Malignancies

Interventions

DRUG

Tisotumab Vedotin

Tisotumab vedotin is an antibody-drug conjugate (ADC) targeting tissue factor (TF), a protein aberrantly expressed in a wide number of solid tumors including cervical cancer.

Trial Locations (1)

250013

Jinan Central Hospital, Jinan

All Listed Sponsors

lead

Zai Lab (Shanghai) Co., Ltd.

INDUSTRY

NCT05866354 - To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies | Biotech Hunter | Biotech Hunter